Financial PerformanceCodexis reported better-than-expected financial results for 2Q25, including revenues of $15.3 million, up from $8.0 million in the previous year period, and a reduced net loss of $13.3 million or ($0.16) per share versus a net loss of $22.8 million or ($0.32) per share in 2Q24.
Partnerships And CollaborationsCodexis related that it now has over 30 engagements with ECO Synthesis partners at present, up from 5-10 at the start of the year, and the company expects to achieve pilot scale production of GLP-grade siRNA material using the ECO Synthesis Innovation Lab by the end of the year.